

NEURON BIO

Neuron Bio specializes in the development of biosolutions for the pharmaceutical and agro-food industries via its divisions: BioPharma, Bioservices and Innofood by Neuron.

COMPANY PROFILE as at

05/20/14

| | |
|------------------------|----------------|
| Price | 2,06 |
| Price as at 07/01/2010 | 3,99 |
| Equity Market Value | 9.527.500,00 € |
| Nº of Shares | 4.625.000 |
| Max/Min | 4,39/1,20 |



| Volume | Shares | Turnover | Capital Increases |
|--------|-----------|--------------|-------------------|
| 2014 | 8.179.000 | 24.455.000 € | 2014 0 € |
| 2013 | 1.008.000 | 1.722.000 € | 2013 0 € |
| 2012 | 367.000 | 1.147.000 € | 2012 0 € |
| 2011 | 615.000 | 1.452.000 € | 2011 0 € |
| 2010 | 1.539.000 | 5.963.000 € | 2010 0 € |

| | | | |
|--------|------------------|-------------------------------------|---------|
| Ticker | NEU | Perc. of Equity Market Value in MAB | 0,36% |
| Sector | Biotech / Pharma | Price Performance since 07/01/2010 | -48,371 |

| Price Performance per year (%) | 2010 | 2011 | 2012 | 2013 | 2014 |
|--------------------------------|---------|---------|---------|---------|--------|
| Neuron | -24,812 | -30,000 | 14,286 | -35,417 | 32,903 |
| MAB Index | -37,679 | -6,312 | 2,293 | 183,437 | 56,701 |
| IBEX Small Cap Index | -18,316 | -25,102 | -24,448 | 44,290 | 15,942 |
| IBEX 35 Index | -17,428 | -13,113 | -4,655 | 21,417 | 5,766 |


MAJOR SHAREHOLDERS

| | |
|------------------------------------|--------|
| Javier Tallada García de la Fuente | 16,76% |
| Minority shareholders | 83,24% |




NEU vs IBEX 35


Sales Revenue




Ebitda



Net Income



Volume



NEURON BIO

Neuron Bio specializes in the development of biosolutions for the pharmaceutical and agro-food industries via its divisions: BioPharma, Bioservices and Innofood by Neuron.

INCOME (Annual)

| | 2011 | 2012 | 2013 | Variation |
|----------------------|----------------------|----------------------|------------------------|---------------|
| Sales Revenue | 418.316,00 € | 200.261,00 € | 53.073,00 € | -73% |
| Ebitda | -563.507,00 € | -774.034,00 € | -531.177,00 € | 31% |
| Ebitda Margin | <i>n.a.</i> | <i>n.a.</i> | <i>n.a.</i> | |
| Net Income | -631.289,00 € | 98.668,00 € | -1.138.865,00 € | -1254% |
| Net Margin | <i>n.a.</i> | 49% | <i>n.a.</i> | |

| Performance Information | 2011 | 2012 | 2013 | *2014 |
|-------------------------------|-----------|-----------|-----------|-----------|
| ROE | N.A. | 0,97% | N.A. | N.A. |
| ROA | N.A. | N.A. | N.A. | N.A. |
| Equity Market Value / Sales** | 23,22 | 55,43 | 135,07 | 179,52 |
| Equity Market Value / EBITDA | N.A. | N.A. | N.A. | N.A. |
| EPS | N.A. | 0,02 € | N.A. | N.A. |
| PER | N.A. | 112,50 | N.A. | N.A. |
| Return Rate | N.A. | 0,89% | N.A. | N.A. |
| Nº of Shares | 4.625.000 | 4.625.000 | 4.625.000 | 4.625.000 |
| Price as at 12-31 | 2,10 | 2,40 | 1,55 | N.A. |
| Price as at 30-04-14 | | | | 2,06 |





*2014 data is price as at 05-20-14 & last public Financial Statements.

**Sales Revenue



There is no forecast from the Company.

| | 2014E | 2015E | 2016E |
|-------------------------------|-------|-------|-------|
| Equity Market Value / Sales** | N.A. | N.A. | N.A. |
| Equity Market Value / EBITDA | N.A. | N.A. | N.A. |
| EPS | N.A. | N.A. | N.A. |
| PER | N.A. | N.A. | N.A. |



| Debt Analysis | 2011 | 2012 | 2013 |
|----------------------|------|------|------|
| Total debt/Ebitda | N.A. | N.A. | N.A. |
| Ebitda/Finance Costs | N.A. | N.A. | N.A. |
| Total debt/Equity | 1,12 | 1,36 | 1,88 |